leflunomide has been researched along with Macrophage Activation Syndrome in 1 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Macrophage Activation Syndrome: A serious complication of childhood systemic inflammatory disorders that is thought to be caused by excessive activation and proliferation of T-LYMPHOCYTES and MACROPHAGES. It is seen predominantly in children with systemic onset JUVENILE IDIOPATHIC ARTHRITIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ricci, M | 1 |
| Rossi, P | 1 |
| De Marco, G | 1 |
| Varisco, V | 1 |
| Marchesoni, A | 1 |
1 other study available for leflunomide and Macrophage Activation Syndrome
| Article | Year |
|---|---|
Macrophage activation syndrome after leflunomide treatment in an adult rheumatoid arthritis patient.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Macrophage Acti | 2010 |